Search

Your search keyword '"Honda, Fumi"' showing total 25 results
Start Over Author "Honda, Fumi"
25 results on '"Honda, Fumi"'

2. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma

Author

Teraoka, Yuji, Kimura, Tomoki, Aikata, Hiroshi, Daijo, Kana, Osawa, Mitsutaka, Honda, Fumi, Nakamura, Yuki, Morio, Kei, Morio, Reona, Hatooka, Masahiro, Kobayashi, Tomoki, Nakahara, Takashi, Murakami, Eisuke, Nagaoki, Yuko, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Kawakami, Yoshiiku, Nagata, Yasushi, and Chayama, Kazuaki

Published
2018
Full Text
View/download PDF

3. Emergence of drug resistance‐associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir‐treated chronic hepatitis C patients

Author

Kan, Hiromi, Imamura, Michio, Kawakami, Yoshiiku, Daijo, Kana, Teraoka, Yuji, Honda, Fumi, Nakamura, Yuki, Morio, Kei, Kobayashi, Tomoki, Nakahara, Takashi, Nagaoki, Yuko, Kawaoka, Tomokazu, Tsuge, Masataka, Aikata, Hiroshi, Hayes, Clair Nelson, Miki, Daiki, Ochi, Hidenori, Honda, Yoji, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, and Chayama, Kazuaki

Published
2017
Full Text
View/download PDF

6. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers

Author

Hatooka, Masahiro, Kawaoka, Tomokazu, Aikata, Hiroshi, Honda, Fumi, Nakamura, Yuki, Nakano, Norihito, Morio, Kei, Fukuhara, Takayuki, Kobayashi, Tomoki, Nagaoki, Yuko, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Kawakami, Yoshiiku, Awai, Kazuo, and Chayama, Kazuaki

Subjects
RECIST, Hepatocellular carcinoma, Tumor marker, Hepatic arterial infusion chemotherapy, digestive system diseases
Abstract

To assess the outcome of stable disease (SD) patients with advanced hepatocellular carcinoma (HCC) by tumor markers after the first course of hepatic arterial infusion chemotherapy (HAIC). The study subjects were 156 HCC patients treated with HAIC and classified as Child Pugh A, with no extrahepatic metastasis, and no history of sorafenib treatment. In the study and validation cohorts, the AFP and DCP ratios of patients who were considered SD to the first course of HAIC were analyzed by AUROC for a prediction of response to the second course of HAIC. The imaging response to the first course of HAIC was classified as partial response (PR), SD and progressive disease (PD) in 29 (18.8%), 80 (51.9%), and 44 (28.6%) patients respectively. For SD patients, the α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) ratios of patients who were considered SD to the first course of HAIC were analyzed by the receiver operating characteristic curve for prediction of response to the second course of HAIC in the study cohorts. The area under the curve of AFP ratio was 0.743. The area under the curve of DCP ratio was 0.695. The cut-off values of AFP and DCP ratios were 1.3 and 1.0, respectively. In the validation cohort, the accuracy of the prediction of response in this validation cohort (71.4%) showed no significant difference compared to that in the study cohort (72.4%) (p = 1.0). The results suggested that patients with a high tumor marker ratio could be switched to alternative therapeutic regimens despite the SD response to HAIC.

Published
2016

7. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis

Author

Hiramatsu, Akira, primary, Aikata, Hiroshi, additional, Uchikawa, Shinsuke, additional, Ohya, Kazuki, additional, Kodama, Kenichiro, additional, Nishida, Yuno, additional, Daijo, Kana, additional, Osawa, Mitsutaka, additional, Teraoka, Yuji, additional, Honda, Fumi, additional, Inagaki, Yuki, additional, Morio, Kei, additional, Morio, Reona, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Tanaka, Junko, additional, and Chayama, Kazuaki, additional

Published
2019
Full Text
View/download PDF

8. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy

Author

Nagaoki, Yuko, primary, Imamura, Michio, additional, Nishida, Yuno, additional, Daijo, Kana, additional, Teraoka, Yuji, additional, Honda, Fumi, additional, Nakamura, Yuki, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Kawakami, Yoshiiku, additional, Miki, Daiki, additional, Hiyama, Yuichi, additional, Ochi, Hidenori, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2018
Full Text
View/download PDF

9. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma

Author

Kawaoka, Tomokazu, primary, Aikata, Hiroshi, additional, Kobayashi, Tomoki, additional, Uchikawa, Shinsuke, additional, Ohya, Kazuki, additional, Kodama, Kenichiro, additional, Nishida, Yuno, additional, Daijo, Kana, additional, Osawa, Mitsutaka, additional, Teraoka, Yuji, additional, Inagaki, Yuki, additional, Honda, Fumi, additional, Hatooka, Masahiro, additional, Morio, Kei, additional, Morio, Reona, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Baba, Yasutaka, additional, Awai, Kazuo, additional, and Chayama, Kazuaki, additional

Published
2018
Full Text
View/download PDF

10. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring

Author

Honda, Fumi, primary, Hiramatsu, Akira, additional, Hyogo, Hideyuki, additional, Aikata, Hiroshi, additional, Daijo, Kana, additional, Teraoka, Yuji, additional, Inagaki, Yuki, additional, Morio, Kei, additional, Kobayashi, Tomoki, additional, Nakahara, Takashi, additional, Nagaoki, Yuko, additional, Kawaoka, Tomokazu, additional, Yoneda, Masayasu, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Ochi, Hidenori, additional, and Chayama, Kazuaki, additional

Published
2018
Full Text
View/download PDF

11. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis

Author

Nagaoki, Yuko, primary, Aikata, Hiroshi, additional, Daijyo, Kana, additional, Teraoka, Yuji, additional, Honda, Fumi, additional, Nakamura, Yuki, additional, Hatooka, Masahiro, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Ochi, Hidenori, additional, and Chayama, Kazuaki, additional

Published
2017
Full Text
View/download PDF

12. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

Author

Nagaoki, Yuko, primary, Imamura, Michio, additional, Aikata, Hiroshi, additional, Daijo, Kana, additional, Teraoka, Yuji, additional, Honda, Fumi, additional, Nakamura, Yuki, additional, Hatooka, Masahiro, additional, Morio, Reona, additional, Morio, Kei, additional, Kan, Hiromi, additional, Fujino, Hatsue, additional, Kobayashi, Tomoki, additional, Masaki, Keiichi, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Kawakami, Yoshiiku, additional, Hayes, C. Nelson, additional, Miki, Daiki, additional, Ochi, Hidenori, additional, and Chayama, Kazuaki, additional

Published
2017
Full Text
View/download PDF

13. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma

Author

Teraoka, Yuji, primary, Kimura, Tomoki, additional, Aikata, Hiroshi, additional, Daijo, Kana, additional, Osawa, Mitsutaka, additional, Honda, Fumi, additional, Nakamura, Yuki, additional, Morio, Kei, additional, Morio, Reona, additional, Hatooka, Masahiro, additional, Kobayashi, Tomoki, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Nagaoki, Yuko, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Nagata, Yasushi, additional, and Chayama, Kazuaki, additional

Published
2017
Full Text
View/download PDF

14. Enhanced ultrasonography detection of mucosa-associated lymphoid tissue of the liver with penetrating vessels in a tumor -case report

Author

Kawaoka, Tomokazu, primary, Aikata, Hiroshi, additional, Inagaki, Yuki, additional, Honda, Fumi, additional, Hatooka, Masahiro, additional, Morio, Kei, additional, Morio, Reona, additional, Kobayashi, Tomoki, additional, Nagaoki, Yuko, additional, Hiramatsu, Akira, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Arihiro, Koji, additional, and Chayama, Kazuaki, additional

Published
2017
Full Text
View/download PDF

15. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib

Author

Kawaoka, Tomokazu, primary, Aikata, Hiroshi, additional, Teraoka, Yuji, additional, Inagaki, Yuki, additional, Honda, Fumi, additional, Hatooka, Masahiro, additional, Morio, Kei, additional, Morio, Reona, additional, Kobayashi, Tomoki, additional, Nagaoki, Yuko, additional, Nakahara, Takashi, additional, Hiramatsu, Akira, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, and Chayama, Kazuaki, additional

Published
2017
Full Text
View/download PDF

16. Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid

Author

Honda, Yohji, primary, Aikata, Hiroshi, additional, Honda, Fumi, additional, Nakano, Norihito, additional, Nakamura, Yuki, additional, Hatooka, Masahiro, additional, Morio, Kei, additional, Kobayashi, Tomoki, additional, Fukuhara, Takayuki, additional, Nagaoki, Yuko, additional, Kawaoka, Tomokazu, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, and Chayama, Kazuaki, additional

Published
2016
Full Text
View/download PDF

17. The impact of interferon‐free direct‐acting antivirals on clinical outcome after curative treatment for hepatitis C virus–associated hepatocellular carcinoma: Comparison with interferon‐based therapy.

Author

Nagaoki, Yuko, Imamura, Michio, Nishida, Yuno, Daijo, Kana, Teraoka, Yuji, Honda, Fumi, Nakamura, Yuki, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Kawakami, Yoshiiku, Miki, Daiki, Hiyama, Yuichi, Ochi, Hidenori, Chayama, Kazuaki, and Aikata, Hiroshi

Abstract

Background and Aim: To examine the effect on recurrence and survival of treatment by interferon (IFN)‐free direct‐acting antivirals (DAA) for patients with hepatitis C virus (HCV)‐associated hepatocellular carcinoma (HCC) who underwent primary curative treatment. Methods: This was a retrospective cohort study of 250 patients with HCV who had received curative treatment for primary HCC. As anti‐HCV treatment after HCC treatment, 38 patients received IFN‐free DAA therapy (DAA patients) and 94 received IFN‐based therapy (IFN patients). The recurrence of HCC and overall survival of the patient groups were compared in a case‐control study. Results: The cumulative HCC recurrence rates at 1, 3, and 5 years were 5%, 39%, and 39% for DAA patients and 0%, 46%, and 62% for IFN patients, respectively (P = 0.370). Multivariate analysis of the HCC recurrence identified treatment responses (sustained virological response [SVR]: hazard ratio [HR] 2.237; P = 0.003) as an independent predictive factor. The cumulative overall survival rates at 3 and 5 years were 96%, 96% for DAA patients and 93%, 73% for IFN patients, respectively (P = 0.163). Multivariate analysis identified treatment responses (SVR: HR 8.742; P < 0.001) as independent predictors of overall survival. Propensity score matching analysis showed no significant difference in HCC development rates and overall survival rates in the two groups. Conclusions: We found that SVR obtained after curative treatment for primary HCC suppressed recurrence and improved overall survival. And, IFN‐free DAA therapy after curative treatment for primary HCC could predict improving overall survival and suppressed HCC recurrence. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction

Author

Nakamura, Yuki, primary, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Teraoka, Yuji, additional, Daijo, Kana, additional, Honda, Fumi, additional, Morio, Kei, additional, Kobayashi, Tomoki, additional, Nakahara, Takashi, additional, Nagaoki, Yuko, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, Hayes, C. Nelson, additional, Miki, Daiki, additional, Ochi, Hidenori, additional, and Chayama, Kazuaki, additional

Published
2016
Full Text
View/download PDF

19. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection

Author

Nakamura, Yuki, primary, Aikata, Hiroshi, additional, Fukuhara, Takayuki, additional, Honda, Fumi, additional, Morio, Kei, additional, Morio, Reona, additional, Hatooka, Masahiro, additional, Kobayashi, Tomoki, additional, Nagaoki, Yuko, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Ochi, Hidenori, additional, Kobayashi, Tsuyoshi, additional, Ohdan, Hideki, additional, Shiroma, Noriyuki, additional, Arihiro, Koji, additional, and Chayama, Kazuaki, additional

Published
2016
Full Text
View/download PDF

20. Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases

Author

Nakano, Norihito, primary, Kawaoka, Tomokazu, additional, Aikata, Hiroshi, additional, Honda, Fumi, additional, Nakamura, Yuki, additional, Morio, Kei, additional, Hatooka, Masahiro, additional, Fukuhara, Takayuki, additional, Kobayashi, Tomoki, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Takahashi, Shoichi, additional, and Chayama, Kazuaki, additional

Published
2016
Full Text
View/download PDF

21. Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma

Author

Kobayashi, Tomoki, primary, Aikata, Hiroshi, additional, Honda, Fumi, additional, Nakano, Norihito, additional, Nakamura, Yuki, additional, Hatooka, Masahiro, additional, Morio, Kei, additional, Morio, Reona, additional, Fukuhara, Takayuki, additional, Masaki, Keiichi, additional, Nagaoki, Yuko, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Kawakami, Yoshiiku, additional, Ohdan, Hideki, additional, Awai, Kazuo, additional, and Chayama, Kazuaki, additional

Published
2016
Full Text
View/download PDF

22. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus‐related cirrhosis.

Author

Nagaoki, Yuko, Aikata, Hiroshi, Daijyo, Kana, Teraoka, Yuji, Honda, Fumi, Nakamura, Yuki, Hatooka, Masahiro, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Kawaoka, Tomokazu, Miki, Daiki, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Kawakami, Yoshiiku, Ochi, Hidenori, and Chayama, Kazuaki

Subjects
ESOPHAGEAL varices, HEPATIC encephalopathy, NUCLEOSIDES, HEPATITIS B virus, COMPUTED tomography, DISEASE risk factors
Abstract

Aim: The aim of this study was to determine the risk factors for worsening of gastroesophageal varices (GEVs) and development of portosystemic encephalopathy in patients with hepatitis B virus (HBV)‐related cirrhosis during nucleos(t)ide analog (NA) treatment. Methods: One hundred and thirty‐seven patients with HBV‐related cirrhosis were enrolled in this retrospective cohort study. Findings of portal hemodynamics with computed tomography, liver function, and endoscopic examinations during NA treatment were assessed. Results: Among 137 patients, feeding vessels for GEVs (left gastric vein, posterior gastric vein, and short gastric vein) were present in 56 (41%) patients, and extrahepatic portosystemic shunt (paraesophageal vein, paraumbilicul vein, and splenorenal shunt) were present in 36 (26%) patients at the start of NA treatment. Although NA treatment was successful, significant improvements were not observed in portosystemic collateral vessels 3 years after NA treatment and GEVs were exacerbated in 48 (35%) patients. The cumulative 5‐ and 10‐year exacerbation rate of GEVs was 27% and 50%, respectively. By multivariate analysis, the existence of feeding vessels for GEVs at the start of NA treatment was the independent predictive factor for the exacerbation of GEVs (P < 0.001). Eight patients who had extrahepatic portosystemic shunt at the start of NA treatment developed portosystemic encephalopathy during follow‐up. The 3‐ and 5‐year incidence of that was 5% and 8%, respectively. Conclusions: The presence of portosystemic collateral vessels at the start of NA treatment increases the risk of GEVs worsening and development of portosystemic encephalopathy in patients with HBV‐related cirrhosis, despite improvement of liver function and success in reducing viral loads with NA treatment. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

23. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection.

Author

Nakamura, Yuki, Aikata, Hiroshi, Fukuhara, Takayuki, Honda, Fumi, Morio, Kei, Morio, Reona, Hatooka, Masahiro, Kobayashi, Tomoki, Nagaoki, Yuko, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Kawakami, Yoshiiku, Ochi, Hidenori, Kobayashi, Tsuyoshi, Ohdan, Hideki, Shiroma, Noriyuki, Arihiro, Koji, and Chayama, Kazuaki

Subjects
FIBROSIS, HEPATITIS C, LIVER surgery, CONFIDENCE intervals, RANK correlation (Statistics), DIAGNOSIS
Abstract

Aim FibroScan is a tool for the non-invasive diagnosis of hepatic fibrosis. Previous studies have compared liver stiffness to percutaneous liver biopsy findings, but no study has compared liver stiffness to liver resection specimen findings. The aim of this study was to compare FibroScan measurements to resected liver specimen findings. Methods From April 2011 to November 2015, a total of 114 patients with liver tumor and hepatitis C were enrolled. We divided them into two groups, the training set and validation set. Liver stiffness was measured by FibroScan before surgery, and specimens obtained by liver resection were evaluated according to the METAVIR system. Results Using Spearman's rank correlation analysis, a positive correlation between liver stiffness measurement and liver fibrosis stage was observed ( r = 0.786, P ≤ 0.0001). In the training set, the area under receiver operating curves for diagnosis of F ≥ 2 was 0.971 (95% confidence interval, 0.928-1.000; cut-off value, 5.9), for diagnosis of F ≥ 3 was 0.911 (0.825-0.997, 9.8), and for diagnosis of F = 4 was 0.917 (0.849-0.985, 15.5). In the validation set, at a cut-off value of 5.9 kPa, sensitivity, specificity, positive predictive values, and negative predictive values for F ≥ 2 were 95.7%, 0.0%, 97.8%, and 0.0%, respectively, of 9.8 kPa for F ≥ 3 were 86.2%, 52.6%, 73.5%, and 71.4%, and of 15.5 kPa for F = 4 were 100%, 71.8%, 45.0%, and 100%. Conclusions The stage of stiffness graded by FibroScan has a good correlation with the liver fibrosis of resected liver specimens. It has the ability to diagnose fibrosis stage non-invasively. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

24. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

Author

Nakamura, Yuki, Imamura, Michio, Kawakami, Yoshiiku, Teraoka, Yuji, Daijo, Kana, Honda, Fumi, Morio, Kei, Kobayashi, Tomoki, Nakahara, Takashi, Nagaoki, Yuko, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Aikata, Hiroshi, Hayes, C. Nelson, Miki, Daiki, Ochi, Hidenori, and Chayama, Kazuaki

Abstract

Chronic hepatitis C virus (HCV) infection is associated with renal dysfunction. Daclatasvir and asunaprevir combination therapy showed a high virological response for genotype 1 chronic HCV-infected patients with renal dysfunction on hemodialysis. However, the safety and efficacy of the therapy for patients with renal dysfunction who are not on hemodialysis are not well-known. In total, 147 patients with chronic HCV genotype 1 infection were treated with 24 weeks of daclatasvir plus asunaprevir therapy. Among these patients, 126 had normal renal function (estimated glomerular filtration rate [eGFR] ≥ 50 ml/min/1.73 m2) and 21 had renal dysfunction (eGFR < 50 ml/min/1.73 m2). Plasma concentrations of daclatasvir and asunaprevir after 5 days of treatment were the same in the normal renal function and renal dysfunction groups. Early virological response (4, 8, 48, 96, and 168 hr after the start of the therapy) was similar between the two groups. End-of-treatment response was achieved in 122 (96.8%) and 20 (95.2%) patients with normal renal function and with renal dysfunction, respectively, and sustained virological response was achieved in 119 (94.4%) and 20 (95.2%) patients. The frequency of adverse events was also comparable between the two groups. Treatment discontinuation due to adverse events was required for only one patient in each group. Renal function did not change either during or after treatment in both groups. In conclusion, renal function is unlikely to have a significant impact on blood kinetics of daclatasvir and asunaprevir. This combination therapy was effective and safe for patients without hemodialysis. J. Med. Virol. 89:665-671, 2017. © 2016 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results